EGI
VKTX icon

EAM Global Investors’s Viking Therapeutics VKTX Stock Holding History

EAM Global Investors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-211,228
Closed -$1.99M – 195
2022
Q4 		$1.99M Buy
+211,228
New +$943K 0.51% 73
2019
Q1 		– Sell
-115,781
Closed -$886K – 158
2018
Q4 		$886K Hold
115,781
– – 0.49% 105
2018
Q3 		$2.02M Hold
115,781
– – 0.82% 26
2018
Q2 		$1.1M Sell
115,781
-96,764
-46% -$644K 0.54% 114
2018
Q1 		$929K Sell
212,545
-33,975
-14% -$188K 0.48% 114
2017
Q4 		$1M Buy
+246,520
New +$716K 0.51% 90

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

EAM Global Investors's VKTX Position: Q1 2023 in Review

EAM Global Investors sold out of Viking Therapeutics (VKTX) in Q1 2023, closing a stake of 211,228 shares — an estimated $1.99M sold.

EAM Global Investors first reported a position in VKTX in Q4 2017 and held it in 6 quarters. The position peaked at $2.02M in Q3 2018. 184 funds tracked by Wall St. Rank hold VKTX as of Q1 2023.

  • EAM Global Investors reported no remaining Viking Therapeutics position as of Q1 2023 after selling out during the quarter.
  • EAM Global Investors sold 211,228 Viking Therapeutics shares in Q1 2023, an estimated $1.99M.
  • EAM Global Investors first reported a position in Viking Therapeutics in Q4 2017 and held it in 6 quarters.
  • EAM Global Investors's Viking Therapeutics position peaked at $2.02M in Q3 2018.
  • 184 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2023.

Based on EAM Global Investors's 13F filing for Q1 2023, filed 15 May 2023.